Back to results
US 6,333,326 B1Granted
Quinoxalinediones
AssigneePfizer Inc.
InventorsAlan Stobie, Elisabeth Colette Louise Gautier, David Charles Waite, Robert James Crook
Life of this patent
Estimating the term…
Abstract
This invention relates to 2,3(1H,4H)-quinoxalinedione derivatives which are selective antagonists of N-methyl-D-aspartate receptors. More particularly, this invention relates to 5-triazolyl-2,3(1H,4H)-quinoxalinedione derivatives and to the preparation of, compositions containing, and the uses of, such derivatives. It also relates to a method for treating acute neurodegeneration disorders and chronic neurological disorders.
Claims16
A substantially pure compound of the formula:
- or a pharmaceutically acceptable salt thereof.
A compound of the formula:
- wherein R is group of the formula:
- and R1 and R2, either when taken alone or together, represent a group or groups that can be hydrolytically cleaved under acidic or basic conditions to provide the corresponding quinoxalinedione.
A compound of the formula:
- wherein R3 is a group of the formula:
- and R1 and R2 are either each independently selected from C1-C4 alkyl (preferably methyl or ethyl) and benzyl, optionally ring substituted by from 1 to 3 substituents each independently selected from C1-C4 alkyl, C1-C4 alkoxy, halo nitro and trifluoromethyl, or, when taken together, represent C1-C6 alkylene CH(phenyl), CH(4-methoxypenyl) or CH(3,4-dimiethoxyphenyl).
Dependencies are inferred from the claim text.